<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12176">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00510497</url>
  </required_header>
  <id_info>
    <org_study_id>Riddler 055794</org_study_id>
    <secondary_id>5U19AI055794</secondary_id>
    <nct_id>NCT00510497</nct_id>
  </id_info>
  <brief_title>Autologous Dendritic Cell Vaccine in HIV1 Infection</brief_title>
  <official_title>Phase I/II Evaluation of Therapeutic Immunization With Autologous Dendritic Cells Pulsed With Autologous, Inactivated HIV-1 Infected, Apoptotic Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sharon Riddler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: University of Pittsburgh Data Safety and Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to look at the safety and tolerability of immunization with dendritic cell
      vaccine prepared using the patient's own cells and virus. It also aims to explore the
      virologic efficacy of the vaccine as determined by a decrease in the viral load 12 weeks
      after analytic treatment interruption.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/II, open label, single-arm, single-site clinical trial designed to
      evaluate the safety and antiviral activity of the ApB DC vaccine, a therapeutic vaccine
      derived from autologous dendritic cells loaded with autologous HIV-1 infected apoptotic
      cells. The study will be conducted in three phases. The first is the pre-vaccination phase
      that includes study entry, isolation of autologous virus, and initiation of antiretroviral
      therapy. Once the patient's viral load has been suppressed to undetectable levels (&lt;50
      copies/mL) and sufficient virus has been isolated, the second phase will begin. This
      includes leukapheresis in order to harvest monocytes and lymphocytes necessary for vaccine
      preparation. Three vaccine doses will be administered subcutaneously every other week. Six
      weeks after the last vaccination, the third phase, analytic treatment interruption (ATI)
      phase, will begin. A fourth, booster dose of vaccine will be given two weeks after the start
      of treatment interruption. The treatment interruption will be continued for twelve weeks
      after which the primary HIV provider will decide whether or not antiretroviral therapy
      should be restarted. CD4 and viral load will be closely monitored throughout the study
      especially during treatment interruption. Follow-up will be continued for 24 weeks after the
      12-week treatment interruption.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine.</measure>
    <time_frame>80 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE graded by Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 1.0, December 2004</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virologic Efficacy (HIV-1 Viral Load at End of ATI Minus Viral Load Prior to ART)</measure>
    <time_frame>at the end of 12 weeks treatment interruption</time_frame>
    <safety_issue>No</safety_issue>
    <description>Log10 Change in HIV RNA set point comparing pre-ART to 12 weeks after treatment interruption</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who will receive ApB Dendritic cell vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous HIV-1 ApB DC Vaccine</intervention_name>
    <description>Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed HIV-1 infection.

          -  CD4 greater than or equal to 350 cells/mL within 8 weeks prior to study entry.

          -  Plasma HIV-1 RNA level of 5000-100,000 copies/mL within 8 weeks prior to study entry.

          -  Antiretroviral therapy naive.

          -  Willingness to interrupt ART for at least 12 weeks.

          -  Written informed consent.

        Exclusion Criteria:

          -  Treatment within 30 days prior to study entry with systemic steroids or other
             immunosuppressives, or any underlying disease which may require use of such
             medications during the study period.

          -  Receipt of any vaccinations other than routine ones within 6 months of study entry

          -  Pregnancy or breastfeeding

          -  Previous or current CDC Category C event

          -  Receipt of any investigational product within 12 weeks prior to study entry.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon A Riddler, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 3, 2016</lastchanged_date>
  <firstreceived_date>August 1, 2007</firstreceived_date>
  <firstreceived_results_date>January 12, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Sharon Riddler</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>dendritic cell</keyword>
  <keyword>therapeutic vaccine</keyword>
  <keyword>HIV-1</keyword>
  <keyword>apoptotic cells</keyword>
  <keyword>Phase I/II</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Autologous HIV-1 ApB DC Vaccine</title>
          <description>Subjects who will receive ApB Dendritic cell vaccine
Autologous HIV-1 ApB DC Vaccine: Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>11 particpants were enrolled but one received no study vaccines and was withdrawn and not included in any analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>Autologous HIV-1 ApB DC Vaccine</title>
          <description>Subjects who will receive ApB Dendritic cell vaccine
Autologous HIV-1 ApB DC Vaccine: Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="37.9" lower_limit="20" upper_limit="54"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine.</title>
        <description>AE graded by Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 1.0, December 2004</description>
        <time_frame>80 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Autologous HIV-1 ApB DC Vaccine</title>
            <description>Subjects who will receive ApB Dendritic cell vaccine
Autologous HIV-1 ApB DC Vaccine: Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine.</title>
            <description>AE graded by Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 1.0, December 2004</description>
            <units>participants with Grade 3 events related</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Efficacy (HIV-1 Viral Load at End of ATI Minus Viral Load Prior to ART)</title>
        <description>Log10 Change in HIV RNA set point comparing pre-ART to 12 weeks after treatment interruption</description>
        <time_frame>at the end of 12 weeks treatment interruption</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Autologous HIV-1 ApB DC Vaccine</title>
            <description>Subjects who will receive ApB Dendritic cell vaccine
Autologous HIV-1 ApB DC Vaccine: Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Virologic Efficacy (HIV-1 Viral Load at End of ATI Minus Viral Load Prior to ART)</title>
            <description>Log10 Change in HIV RNA set point comparing pre-ART to 12 weeks after treatment interruption</description>
            <units>log10 HIV RNA</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.21" lower_limit="-0.60" upper_limit="0.22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Autologous HIV-1 ApB DC Vaccine</title>
          <description>Subjects who will receive ApB Dendritic cell vaccine (does not include one enrolled participant who received no study treatment)
Autologous HIV-1 ApB DC Vaccine: Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>grade 3 severe pruritus and injection site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sharon A. Riddler, MD, MPH</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-383-1675</phone>
      <email>riddler@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
